SK Biopharm to Expand R&D Capabilities with Acquisition of ProteoVant Sciences

SEOUL, June 30 (Korea Bizwire) — SK Biopharmaceuticals announced on Friday its acquisition of 40 million shares of ProteoVant Sciences, a US-based research and development company, for 62 billion won (US$47 million). The purchase includes all shares held by Roivant Science, ProteoVant’s largest shareholder with a 60% stake. SK holdings, the parent company of SK [...]